Skip to content

Reliability of a Food Frequency Questionnaire in the Assessment of Dietary Intake Including FODMAPs in Different Populations, and Relationship With IBS Symptoms and the Degree of Self-assessed Physical Activity

Reliability of a Food Frequency Questionnaire in the Assessment of Dietary Intake Including FODMAPs (Fermentable Oligosaccharides, Disaccharides, Monosaccharides and Polyols) in Different Populations, and Relationship With IBS (Inflammatory Bowel Syndrome) Symptoms and the Degree of Self-assessed Physical Activity

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05293769
Enrollment
400
Registered
2022-03-24
Start date
2022-10-15
Completion date
2030-12-31
Last updated
2025-12-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Irritable Bowel Syndrome

Brief summary

During an online assessment participants will fill in questionnaires evaluating demographic data, psychological variables, the degree of self-assessed physical activity and symptoms of irritable bowel. Dietary intake will be assessed by a newly developed food frequency questionnaire (FFQ) and a 4 days food diary. In order to validate the FFQ in different populations, participants will be recruited from university students, staff of UZ Brussel and VUB, and from the community by advertisement (including social media). IBS patients will be recruited from the gastro-enterology outpatient clinic.

Interventions

OTHERquestionnaire

questionnaire will be filled in by all participants

Sponsors

Universitair Ziekenhuis Brussel
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years

Inclusion criteria

* 18 - 65 years; * Provide written informed consent; * Living in Belgium

Exclusion criteria

* Diet \< 8 weeks prior to participation; * Known or suspected eating disorder; * Major psychiatric disorder; * Known gastro-intestinal disease (IBS is allowed); * Any malignancy in the past 3 years (basocellular carcinoma is allowed); * Chemotherapy in the past 6 months; * Infectious gastro-enteritis in the past 6 months (infectious gastro-enteritis defined as the concurrent presence of one of the following signs during 2 or more consecutive days: fever, vomiting, sudden onset of diarrhea, hospitalization because of these symptoms); * Previous abdominal surgery (appendectomy and cholecystectomy are allowed); * Alcohol abuse defined as \> 14 U per week; * Use of illicit drugs; * Intake of drugs with known major gastro-intestinal side effects. * Initiation of neuromodulators less than 3 months before participation. Neuromodulators are allowed when taken at a stable dose for at least 3 months; * Pregnancy.

Design outcomes

Primary

MeasureTime frame
To validate the newly developed food frequency questionnaire against the standard 4-day food diary across different populations2 years

Secondary

MeasureTime frameDescription
Comparison of dietary and FODMAP intake in IBS vs. non-IBS patients in different populations2 yearsdifferences in number and type of FODMAP intake between groups
Comparison of the degree of physical activity in IBS vs. non-IBS patients in different populations2 yearsdifferences and correlation of IPAQ (International Physical Activity Questionnaire) scores between groups, IPAQ evaluates the level of physical activity. Scoring a HIGH level of physical activity on the IPAQ means your physical activity levels equate to approximately one hour of activity per day or more
Comparison of the degree of physical activity and IBS symptom severity in different populations2 yearsdifferences and correlation of IPAQ scores between groups; IPAQ evaluates the level of physical activity. Scoring a HIGH level of physical activity on the IPAQ means your physical activity levels equate to approximately one hour of activity per day or more

Countries

Belgium

Contacts

Primary ContactSébastien Kindt
Sebastien.kindt@uzbrussel.be+32 2 477
Backup ContactVirgini Van Buggenhout
virgini.vanbuggenhout@uzbrussel.be+32 2 477

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026